Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × INDUSTRY × rrCLL × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 470 Carcinoma, Non-Small-Cell Lung 438 Breast Neoplasms 331 Neoplasm Metastasis 240 Colorectal Neoplasms 211 Melanoma 210 Leukemia, Myeloid, Acute 191 Multiple Myeloma 177 Ovarian Neoplasms 169 Recurrence 166 Prostatic Neoplasms 162 Lymphoma, Non-Hodgkin 147 Lung Neoplasms 129 Pancreatic Neoplasms 124 Lymphoma 122 Carcinoma, Renal Cell 111 Leukemia, Lymphocytic, Chronic, B-Cell 110 Squamous Cell Carcinoma of Head and Neck 106 Stomach Neoplasms 92 Carcinoma, Hepatocellular 89 Leukemia 87 Triple Negative Breast Neoplasms 86 Lymphoma, Large B-Cell, Diffuse 85 Lymphoma, Follicular 81 Head and Neck Neoplasms 78 Glioblastoma 73 Myelodysplastic Syndromes 70 Urinary Bladder Neoplasms 67 Small Cell Lung Carcinoma 63 Precursor Cell Lymphoblastic Leukemia-Lymphoma 55

Interventions

pembrolizumab 1 dinaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02684617 2021-03-01

KEYNOTE-155

Merck Sharp & Dohme LLC

Phase 1 Terminated

75 enrolled 17 charts

rrCLL

Data powered by HemOnc (CC BY 4.0) Colophon ⚡